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Summary
The skin contains readily accessible dendritic cells
(DCs) with potent antigen presentation function and
functional plasticity enabling the integration of anti-
gen specificity with environmentally responsive im-
mune control. Recent studies challenge the estab-
lished paradigm of cutaneous immune function by
suggesting that lymph node-resident DCs, rather
than skin-derived DCs (sDCs), are responsible for elic-
iting T cell immunity against cutaneous pathogens in-
cluding viral vectors.We show that cutaneous delivery
of lentivirus results in direct transfection of sDCs and
potent and prolonged antigen presentation. Further,
sDCs are the predominant antigen-presenting cells
for the induction of potent and durable CD8+ T cell im-
munity. These results support the classical paradigm
of cutaneous immune function and suggest that anti-
gen presentation by sDCs contributes to the high
potencyof lentivector-mediatedgenetic immunization.
Introduction
The skin is rich in readily accessible DCs and has long
been regarded as a highly immunogenic target for vac-
cine delivery (Larrengina and Falo, 2005; Glenn et al.,
2003). Recent observations support this notion by dem-
onstrating that, in human subjects, administration of the
common protein-based flu vaccine intradermally is sig-
nificantly more immunogenic than intramuscular immu-
nization (Belshe et al., 2004; Kenney et al., 2004; La Mon-
tagne and Fauci, 2004). Understanding the skin immune
network and the mechanisms of cutaneous immuniza-
tion is critically important for the future development of
efficacious vaccines and immunotherapies against in-
fectious agents and neoplastic diseases, and potentially
for the development of ‘‘suppressive’’ immunotherapies
to alleviate autoimmune disease.
Skin contains both epidermal (Langerhans cells, LCs)
and dermal DCs, and skin-draining lymph nodes (DLNs)
contain both resident and skin-derived DC (sDC) popu-
lations. In the classical paradigm, antigens delivered to
the skin are taken up by ‘‘immature’’ skin-resident
DCs, which, in response to natural or adjuvant induced
‘‘danger signals,’’ migrate to the skin DLNs. These
sDCs can then present antigen (signal 1) to lymph
node (LN) resident T cells and provide both costimula-
*Correspondence: ykhe@pitt.edu (Y.H.); lof2@pitt.edu (L.D.F.)tory signals (signal 2) necessary for T cell activation
and memory induction, and integrated environmental
stimuli (signal 3) that influence immune skewing respon-
sive to conditions in the periphery (Banchereau and
Steinman, 1998). In this way, sDCs ‘‘integrate’’ antigen
specificity and environmentally responsive immunomo-
dulation. However, recent studies have challenged this
paradigm, particularly in regard to CD8+ T cell priming.
Following viral infection, LN resident CD8+ DCs, rather
than sDCs, have been implicated as key antigen-pre-
senting cells (APCs) for priming CD8+ T cell responses
against virally encoded antigens (Allan et al., 2003).
This has been demonstrated for a number of viral vec-
tors including those derived from vaccinia virus (VV),
herpes simplex virus (HSV), and influenza A viruses
(IAV) (Allan et al., 2003; Belz et al., 2004; Smith et al.,
2003).
Understanding the mechanism of immune induction
against virally introduced antigens is of particular inter-
est, given the considerable potential of viral-mediated
genetic immunization (Yewdell and Haeryfar, 2005). In
genetic immunization, antigen presentation can occur
either by in vivo transfection of DCs, resulting in direct
presentation of endogenously synthesized antigen
(Condon et al., 1996; Porgador et al., 1998), or by in
vivo transfection of non-APCs such as keratinocytes or
muscle cells which synthesize large amounts of trans-
genic antigen that can be secreted or crosspresented
as cell-associated antigen (Heath et al., 2004; Kurts
et al., 2001). In addition, viral vectors and plasmid DNA
can serve as potent adjuvants, enhancing and skewing
immune responses (Ada and Ramshaw, 2003; Liu
et al., 2004; Sasaki et al., 2003). Although in many cases
recombinant viral vectors have been shown to be more
potent than other genetic immunization approaches, in-
fection by viral vectors can alter DC function, and im-
mune responses against vector proteins can limit immu-
nity directed against transgenic antigens (Larsson et al.,
2004; Yewdell and Haeryfar, 2005).
Recently, lentivirus has been explored as a vector for
genetic immunization, and preliminary studies suggest
that it is among the most potent vectors for immune in-
duction (He et al., 2005; Esslinger et al., 2003; Esslinger
et al., 2002; Palmowski et al., 2004). Importantly, we and
others have shown that lentivectors efficiently and sta-
bly transfect DCs without apparent alteration of DC
function (He et al., 2005; Breckpot et al., 2003). Lentivec-
tor-transfected DCs can process and present trans-
genic antigens through both the class I and class II re-
stricted processing pathways and prime naive CD8+
and CD4+ T cells (He et al., 2005). Like conventional on-
coretroviral vectors, lentivectors do not encode viral
proteins, reducing the likelihood of antivector immunity.
Here we address the role of sDCs in T cell activation,
and the potency and mechanism of lentivector-medi-
ated genetic immunization. Our studies show that a sin-
gle cutaneous injection of lentivector induces potent an-
tigen-specific lytic activity against model, viral, and
tumor antigens, and therapeutic antitumor immunity.
Lentivector-induced lytic responses persist for longer
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we find that preexposure to immunizing doses of
lentivector does not inhibit the elicitation of an immune
response against an encoded antigen by a second vac-
cination with the same vector, suggesting that vector-
specific immunity does not limit the immunogencity of
lentivector vaccination or boosting at the tested doses.
Importantly, our studies demonstrate that, following cu-
taneous lentivector immunization, the sDC population
(CD11c+CD82/loDEC205+) expresses transgenic anti-
gens and is the predominant DC population capable
of priming CD8+ T cells. These results suggest that, in
contrast to previous reports obtained using HSV, IAV,
and VV vectors, in lentivector-mediated immunization,
sDCs may be the primary DC subset responsible for
the induction of CD8+ T cell immunity. This supports
the classical paradigm of cutaneous immune function
based on the capture, transportation, and presentation
of antigen by sDCs, enabling the integration of antigen
specificity and environmentally responsive immunomo-
dulation. The direct in vivo stable transfection of sDCs
and their role in priming naive T cells likely contribute
to the high potency of lentivector-mediated genetic im-
munization we observe. These results suggest that
lentivirus may have unique advantages as a vector for
genetic immunization.
Results
A Single Injection of Recombinant Lentivector
Induces Potent Antigen-Specific Lytic Activity
against Encoded Antigens
Most plasmid DNA delivery strategies require priming
followed by boosting immunizations with DNA or protein
to achieve potent immune responses (Moore and Hill,
2004). Two of the more extensively studied genetic im-
munization approaches, intramuscular injection of na-
ked DNA and cutaneous biolistic delivery of naked
DNA, can elicit potent lytic responses but generally re-
quire boosting immunizations. To compare the potency
of induced T cell immunity, we delivered a single immu-
nizing dose of OVA expressing naked plasmid DNA intra-
muscularly or by gene gun bombardment and immu-
nized other groups of animals by intradermal injection
of OVA expressing recombinant adenoviral vector
(OVA-Ad), lentivector (OVA-lvv), or vaccinia vector
(OVA-vv). Eight days after immunization, we evaluated
in vivo antigen-specific lytic activity using the well-
described in vivo killing assay (Barchet et al., 2000; He
et al., 2005). As expected, immunization with a single
dose of plasmid DNA did not result in significant levels
of in vivo killing (Figure 1A). In striking contrast, lentivec-
tor-mediated immunization (1 million transduction units,
TU) induced strong antigen-specific in vivo lytic activity,
comparable to that observed following immunization
with highly potent adenoviral vector. Vaccinia vector
immunization induced significant but lower levels of
antigen-specific lytic activity. Consistent with this,
both recombinant adenovirus- and lentivirus-immunized
animals demonstrated significant numbers of antigen-
specific IFN-g-producing CD8+ T cells by intracellular
staining (Figure 1B). Antigen-specific IFN-g-producing
CD8+ T cells were minimally detectable in animals immu-
nized with plasmid DNA or vaccinia vector. Similarlypotent immune responses against clinically relevant
Hepatitis B virus S antigen (HBV S) (Figure 1C) and the
murine melanoma self-antigen TRP2 were induced using
recombinant lentivectors (Figure 1D). Furthermore, a sin-
gle immunization with lentivector OVA-lvv induced tu-
mor specific immunity sufficient to inhibit tumor growth
and prolong survival of tumor bearing animals (Figures
1E and 1F).
A major drawback of adenoviral vector vaccination is
the development of antivector immunity that can limit
the effectiveness of readministration of the vector in
individuals with natural preexisting antivector immunity,
or those who have been previously immunized (Rosen-
berg et al., 1998). To evaluate the limitations imposed
by antivector immune responses, we pretreated mice
with varying doses of recombinant lentivector express-
ing the EGFP gene (EGFP-lvv) and then immunized
mice 12 days later with 1 million TU of OVA-lvv. Preim-
munization with 10 million TU of lentivector encoding
the irrelevant EGFP antigen did not inhibit antigen-spe-
cific immunity induced by the same lentivector encoding
OVA (Figure 1G). Even a 10-fold increase in the dose of
preimmunizing vector (100 million TU of EGFP-lvv) re-
sulted in only partial inhibition of the OVA-specific lytic
response. In contrast, even at low doses, preimmuniza-
tion with adenoviral vector encoding EGFP (10 million
pfu) significantly inhibited the subsequent development
of an OVA-specific response. Higher preimmunization
doses (100 million pfu) completely blocked induction of
OVA-specific lytic responses in mice subsequently im-
munized with OVA-Ad. These data suggest that lentivec-
tor-specific immune responses are less likely to limit len-
tivector immunization and boosting, and consistent with
this, we find that mice immunized with lentivector devel-
oped potent antigen-specific recall responses when re-
immunized with the same vector (see Figure S2 in the
Supplemental Data available with this article online).
We sought to compare the immune response and
mechanisms of immune induction following immuniza-
tion with lentivector, a nonlytic virus without apparent in-
hibitory effects on DC function, to vaccinia vector,
a well-characterized immunization vector representa-
tive of lytic vectors. To evaluate the magnitude and du-
rability of the immune responses, we determined the ki-
netics of in vivo antigen-specific lytic activity induced by
immunization. Following a single immunization with len-
tivector, in vivo killing activity reached a peak in 8 days
and then began to gradually decline (Figure 2A). How-
ever, immunized mice maintained remarkably high kill-
ing activity (>50% of killing) for at least 50 days
(Figure 2A, Figure S2). Even after 4 months, there was
still detectable killing activity of 15% (Figure S2). In addi-
tion, reimmunization at this time with the same lentivec-
tor elicited lytic activity approaching 100% lysis. In
contrast, vaccinia vector immunization resulted in sub-
stantial but significantly less initial lytic activity that
also peaked at day 8 but then decreased rapidly to
near-baseline levels (Figure 2A). Importantly, these dif-
ferences in the kinetics of the immune response corre-
lated with differences in the magnitude and duration of
antigen presentation in vivo. The prolonged immune re-
sponses observed following lentivector immunization
correlated with prolonged antigen presentation in vivo
in the draining LNs (Figure 2B).
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645Figure 1. Immunization with Recombinant
Lentivector Elicits Strong Antigen-Specific
Lytic Activity In Vivo and Effective Antitumor
Immunity
(A–D) Mice were immunized with 1 million TU
of lentivector expressing OVA (A and B), HBV
S antigen (C), or EGFP-TRP2 fusion protein
(D). Immunization by intramuscular injection
(100 mg) or gene gun bombardment (20 mg)
of naked plasmid DNA encoding the same an-
tigen was compared. Groups of mice immu-
nized by injection of 1 million pfu of adeno-
vector or vaccinia vector expressing OVA
(OVA-Ad and OVA-VV) were also included in
(A) and (B). Eight days later, antigen-specific
in vivo killing was determined (4 hr assay for
OVA or 20 hr assay for HBS and TRP2), and
ex vivo intracellular staining for IFN-g was
performed to evaluate the T cell responses
in vivo and in vitro. Mean 6 SD of three
mice is shown for each group, and the exper-
iment was repeated at least three times with
similar results.
(E and F) C57BL/6 mice were inoculated with
0.1 million of B16-OVA cells and immunized
or not (control) 3 days later with 1 million TU
of OVA-lvv or EGFP-lvv encoding the irrele-
vant antigen EGFP. Tumor growth (mean 6
SD of ten mice per group) (E) and survival
(F) were recorded. This experiment was re-
peated twice with similar results.
(G) Mice were preimmunized with different
doses of EGFP-lvv or EGFP-Ad and 12 days
later immunized with 1 million pfu of OVA-
Ad or 1 million TU of OVA-lvv. Another 8
days later, in vivo antigen-specific lytic activ-
ity was measured (20 hr assay). Mean6 SD of
three mice is indicated for each group, and
the experiment was repeated three times
with similar results.sDCs from Lentivector-Immunized Mice Prime Naive
T Cells
Previous reports suggest that LN resident CD8+ DCs,
and not sDCs, are the critical APCs responsible for
crosspriming CD8+ T cells after cutaneous delivery of vi-
ral vectors, calling into question the established para-
digm of sDC function (Allan et al., 2003; Belz et al.,
2004; Carbone et al., 2004; Heath et al., 2004; Smith
et al., 2003). To investigate the role of sDCs in T cell
priming following lentivector immunization, we utilized
the same approaches used in those studies to isolate
DC subsets and measured their ability to stimulate naiveOVA-specific OT-I cells ex vivo (Belz et al., 2004; Smith
et al., 2003).
We first isolated and purified three DC subsets based
on expression of CD11c, CD8, and B220 surface
markers from mice injected via footpad with lentivector
OVA-lvv (Figure S3) and determined their ability to stim-
ulate naive OT-I T cells ex vivo. Sorted DC subsets were
cocultured with CFSE-labelled OT-I cells isolated from
TCR transgenic mice. We found that only CD82/lo DCs
were able to stimulate CFSE-labelled OT-I cell prolifera-
tion manifested by progressive reduction of fluores-
cence intensity of CFSE (Figures 3A and 3B). Neither
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Vaccinia Vector-Mediated Genetic Immunization
(A) Forty mice were immunized with 0.5 million TU of OVA-lvv or 0.5 million pfu of OVA-VV. At each time point shown, three mice were used to
determine in vivo lytic activity. In vivo killing was determined using the 20 hr assay at all time points. At the 8 and 15 day time points where max-
imum killing was observed in OVA-lvv immunized groups, 4 hr assays was also included (right panel). Mean6 SD of three mice is shown for each
time point.
(B) Mice were immunized with 1 million TU of lentivector OVA-lvv or 1 million pfu of vaccinia vector OVA-VV. At the indicated time points, 10 mil-
lion OT-I cells labelled with CFSE were administered through tail vein. Sixty-four hours after injection of OT-I cells, proliferation of OT-I cells in
draining popliteal LNs was determined by progressive dilution of CFSE intensity determined by flow cytometry. M1, nonproliferating OT-I cells.
M2, proliferating OT-I cells.CD8+ DCs nor pDCs induced measurable OT-I T cell
proliferation. Similar results were obtained using the
well-established 3H-thymidine incorporation assay to
evaluate the OT-I cell proliferation (Figure 3C). All DC
populations stimulated strong OT-1 proliferation when
pulsed with the class I restricted peptide SIINFEKL,
verifying that the antigen presentation function of each
subset was intact (Figure 3C).
Cells within the CD82/lo DC subset that includes sDCs
also express CD11b, while the CD8+ LN resident DC
subset does not (Shortman and Liu, 2002). We used
this difference to distinguish these DC subsets based
on expression of the CD8 and CD11b markers. Both
CD82/loCD11b+ and CD8+CD11b2 DCs were isolated
to more than 96% purity (Figure S4). Isolated DC subsets
were then cocultured with OT-I cells to measure the
stimulation of OT-I cell activation using the 3H-thymidine
incorporation assay. Using these alternative markers to
define these subsets, we confirmed that CD82/loCD11b+
DCs prime naive T cells in response to lentivector medi-
ated genetic immunization. As expected from our previ-
ous results, CD8+CD11b2 DCs were unable to induceOT-I cell proliferation ex vivo (Figure 3E). To address ef-
fector function, we also evaluated cytokine secretion by
proliferating OT-I cells elicited by different DC subsets.
A substantial amount of IFN-g was detected in the su-
pernatant of OT-I cells stimulated by CD82/loCD11b+
DCs, but not in supernatants of cells stimulated by
CD8+CD11b2 DCs or CD82/loCD11b2 DCs (Figure 3F).
The concentration of IFN-g in the supernatant of
150,000 OT-I cells reached 30 ng/ml in 72 hr. DC subsets
alone did not produce significant levels of IFN-g (data
not shown).
In the skin-draining LNs, the CD82/lo DCs include LN
resident CD82DEC2052 and skin-derived CD82/lo
DEC205+ that include both LCs and dermal DC popula-
tions. Pure populations of CD82/loDEC205+, CD82/lo
DEC2052, CD8+DEC2052/+ DCs were isolated from
DLNs by cell sorting (Figure S5A). Only CD82/loDEC205+
DCs strongly stimulated OT-I cell proliferation (Fig-
ure 4A). CD8
+
DEC2052/+ DCs induce much lower levels
of OT-I cell proliferation. To directly compare our results
with those obtained using the well-described vaccinia
model, we purified the same subsets from the skin
Immunization Targeting Skin Dendritic Cells
647Figure 3. Stimulation of Naive CD8+ T Cells Ex Vivo by APC Subsets from Lentivector-Immunized Mice
(A) Mice were immunized with 10 million TU of OVA-lvv. Two days later, DLN cells were prepared, and DC subsets were sorted based on expres-
sion of CD11c, B220, and CD8.
(B and C) Twenty thousand DCs of each subsets were cocultured with 150,000 CFSE labelled OT-I cells for 3 days, and then OT-I cell division was
determined by progressive dilution of CFSE intensity (B). Alternatively, DC subsets were cocultured with OT-I cells for 2 days, and OT-1 prolif-
eration was determined by 3H-thymidine incorporation ([C], left panel). Identically treated DC subsets pulsed with SIINFEKL peptide were in-
cluded as controls ([C], right panel). Mean 6 SD of triplicate wells is shown. These experiments were repeated at least five times, and similar
results were observed.
(D) Mice were immunized with 10 million TU of OVA-lvv, and 2 days later DC subsets from DLNs were sorted based on CD11c, CD11b, and CD8.
(E and F). Twenty thousand DCs of each subset were cocultured with 150,000 OT-I cells for 2 days, and then OT-1 proliferation was determined by
3H-thymidine incorporation (E). Supernatants were assayed for the presence of IFN-g by ELISA (F). Mean 6 SD of triplicate wells is shown for
groups in (E) and (F). These experiments were repeated at least five, times and similar results were observed.DLNs of mice immunized with recombinant VV express-
ing OVA (OVA-VV) (Figure S5B). Consistent with previ-
ous reports, we found that, following VV infection, the
endogenous CD8+DEC2052/+ DC subset was the main
DC subset capable of crosspriming naive CD8+ T cells
ex vivo (Figure 4B).
To further substantiate the role of sDCs in antigen pre-
sentation, we utilized the well-established technique of
topical FITC application to identify DCs migrating fromthe skin (Douillard et al., 2005; Itano et al., 2003). Mice
were immunized with lentivector, and then the injection
site was painted with FITC. Two days later, DC subsets
were isolated from the draining lymph node and ana-
lyzed. CD11c+FITC+ and CD11c+FITC2 populations
could be identified and sorted to high purity (Figure 5).
The CD11c+FITC+ DCs predominantly expressed the
CD82/loDEC205+ phenotype consistent with sDCs.
Consistent with previous reports, this CD11c+FITC+
Immunity
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Mice were immunized with 10 million TU of OVA-lvv (A) or 10 million pfu of VV-OVA (B). Two days later, DC subsets from DLNs were sorted based
on expression of CD11c, DEC205, and CD8. Twenty thousand DCs of each subset were cocultured with 150,000 OT-I cells for 2 days, and then
OT-1 proliferation was determined by 3H-thymidine incorporation. Mean6 SD of triplicate wells is shown. This experiment was repeated at least
three times with similar results.population decreased substantially in the LN when we
codelivered pertusis toxin, a DC migration inhibitor
(Douillard et al., 2005; Itano et al., 2003; and data not
shown), further suggesting that these LN resident
CD11c+FITC+ cells migrated from the skin. Functionally,
the CD11c+FITC+ DC subset induced strong prolifera-
tion of OT-1 T cells, indicating that this is the predomi-
nant APC subset.
Transduction of DC Subsets
We sought to account for the pronounced difference in
the mechanism of antigen presentation observed be-
tween lentivector and VV immunization. The striking dif-
ference in antigen presentation between DC subsets
was of particular interest, given accumulating recent
evidence suggesting that presentation by the
CD8+DEC2052/+ DC subset, as exemplified by VV infec-
tion, is characteristic or even required for the generation
of CD8+ T cell responses against viral- and cell-associ-
ated antigens. We hypothesized that, in the case of viral
infection, DC dysfunction or apoptosis induced by infec-
tion limits the antigen presentation ability of infected
cells, resulting in predominance of CD8+DEC2052/+
DC-mediated crosspresentation of secreted or cell-
associated antigens released from dying cells. This is
supported by previous studies suggesting that viral
infection of DCs can limit APC function or induce apo-
ptosis. (Engelmayer et al., 1999; Humlova et al., 2002;
Larsson et al., 2001, 2004; Norbury et al., 2002). In con-
trast, lentivector infection results in stable expression
of transgenic antigens by infected DCs without inhibi-
tion of their APC function or viability (He et al., 2005).To directly compare antigen expression in DLNs fol-
lowing infection with lentivector or VV, we isolated
mRNA from total DLN cells at 6 hr, 24 hr, and 72 hr after
infection and determined OVA gene expression using
semiquantitative RT-PCR. As shown in Figure 6A, OVA
expression appeared early (6 hr) following VV infection,
peaked at 24 hr, and was dramatically reduced by
72 hr. In contrast, following lentivector injection, OVA
expression was first detectable at 24 hr but persisted
and even increased at the 72 hr time point. These results
are consistent with previously reported results for VV
and with the interpretation that VV infection results in
transgene expression followed closely by gene silencing
or death of transfected cells that could provide an anti-
gen source for crosspresentation by CD8+ DCs (Norbury
et al., 2002). In contrast, lentivector administration re-
sults in sustained expression of transgenic antigen in
the DLNs. To more specifically address this issue, we di-
rectly compared the kinetics of antigen expression in
isolated DLN CD82/loDEC205+ and CD8+DEC2052/+ DC
subsets. Following vaccinia vector immunization, OVA
mRNA was detected in both DC subsets at 7 hr, peaked
at 20 hr, and then declined substantially by the 46 hr time
point (Figure 6B). In contrast, OVA mRNA was undetect-
able 7 hr after lentivector immunization but was present
at significant levels at 20 hr and only in the sDC subset.
OVA mRNA levels increased substantially by 46 hr and
continued to be selectively expressed in the sDC sub-
set. These results are consistent with the accumulation
and persistence of migrating antigen-expressing sDCs
in the draining lymph node. Finally, using a lentivector-
expressing luciferase (Luc-lvv), we consistently found
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(A) Mice were immunized with OVA-lvv in the shaved thigh skin, and injection sites were painted with FITC. Two days later, draining LNs were
collected and DCs were enriched from single-cell suspensions. FITC+ and FITC2 DC populations were sorted and analyzed phenotypically.
(B) Sorted CD11c+FITC+ and CD11c+FITC2 DCs were cocultured with OT-I cells in vitro to determine their T cell priming capability. OT-1 pro-
liferation was determined by 3H-thymidine incorporation. Mean 6 SD of triplicate wells is shown. Experiments were repeated twice with similar
results.luciferase activity in the CD82/loDCs (CD11c+CD82/lo
B2202 and CD11c+CD82/loDEC205+ DCs) isolated
form lentivector immunized mice (Figures 6C and 6D,
and Figures S6 and S7). No luciferase activity was de-
tected in CD8a+ (CD11c+ CD8+B2202) or plasmacytoid
(CD11c+CD82/+B220+) DC subsets (Figures 6C and 6D).
These results are consistent with the mechanistic in-
terpretation that lentivector immunization results in sus-
tained expression and presentation of antigen by sDCs,
while vaccinia vector immunization results in substantial
but transient expression of antigen in the draining lymph
nodes. We evaluated and compared DC apoptosis in
lentivector versus vaccinia vector-transduced DC popu-
lations in vitro. Consistent with this interpretation, in vi-
tro infection of DCs by vaccinia vector resulted in rapid
and substantial apoptosis of DCs, while survival of lenti-
vector-infected DCs was comparable to that of untrans-
fected cells throughout the 3 day time course evaluated
(Figure 7A). Furthermore, artificial induction of apopto-
sis (by UVB irradiation) of OVA-lvv-transfected DCs re-
sults in complete inhibition of their ability to stimulate
antigen-specific OT-1 T cells in vitro and in vivo and in-
hibition of antigen-specific lytic activity in vivo (Figures
7B–7D). Thus, unlike vaccinia vector, lentivector trans-
duction does not significantly induce apoptosis of trans-
duced DCs in vitro, and induction of apoptosis of OVA-
lvv-transduced DCs eliminates their ability to directly
present expressed antigens.
Taken together, our data demonstrate that cutaneous
injection of lentivector results in transduction and trans-
gene expression in skin-derived CD82/loDEC205+ DCs.Importantly, in contrast to previous studies using HSV,
IAV, and VV, we demonstrate that, in lentivector immuni-
zation, sDCs can directly prime naive CD8+ T cells, dem-
onstrating an important role for sDCs in the induction of
potent and durable CD8+ T cell immunity.
Discussion
sDCs have long been recognized as potent APCs, capa-
ble of priming naive T cell responses (Green et al., 1980;
Stingl et al., 1980a; Stingl et al., 1980b; Stingl et al., 1977;
Valladeau and Saeland, 2005). Their critical role in im-
mune regulation can be attributed to both this APC func-
tion and functional plasticity that enables them to shape
the nature of the immune responses they induce in re-
sponse to environmental conditions in the periphery.
Because of their remarkable immunoregulatory capacity
and unique accessibility, cutaneous DCs remain the fo-
cus of intense study for the purpose of vaccine develop-
ment, immunotherapy, and efforts to regulate autoim-
munity. Here, we sought to determine the role of sDCs
in inducing CD8+ T cell immunity against cutaneously
introduced antigens.
The traditional paradigm of cutaneous immune func-
tion integrates antigen presentation with immunomodu-
lation by proposing that sDCs both present antigen and
serve as biosensors capable of modulating the nature of
the immune response in response to environmental
stimuli. In this integrative model, sDCs both sample their
antigenic environment in the periphery and translate di-
verse environmental signals encountered there into
Immunity
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(A) Mice were injected with 10 million TUs of OVA-lvv or OVA-VV via footpad. RNA was isolated from total DLN cells at the indicated time points.
OVA transgene expression was determined by RT-PCR. Titrations of varying amounts of total RNA were utilized to semiquantify the abundance
of OVA-specific mRNA. RT-PCR specific for S15 was determined as an internal control. Lv, RNA from OVA-lvv injected mice; VV, RNA from OVA-
VV injected mice.
(B) Mice were injected with 10 million TUs of OVA-lvv or OVA-VV via footpad. At the indicated time points, DC subsets from popliteal and inguinal
LNs were sorted based on expression of CD11c, CD8a, and DEC205. Total RNA was isolated from sorted DC subsets that are >95% pure (data
not shown). One hundred nanograms of total RNA was utilized for RT-PCR to detect OVA specific mRNA. Primers specific for ribosomal protein
S15 were used to measure S15 mRNA as an internal control.
(C and D) Mice were injected with 10 million TUs of Luc-lvv via footpad. Two days later, DC subsets from popliteal and inguinal LNs were sorted
based on expression of CD11c, CD8, and B220 (C) or based on expression of CD11c, CD8a, and DEC205 (D). Luciferase activity was determined
for each subset using luciferase detection reagent (Promega). Mean6 SD of duplicate wells is shown. This experiment was repeated three times
with similar results.a functional program characterized by patterns of ex-
pression of chemokines, cytokines, and cell-surface
molecules that influence trafficking, immune skewing,
and the balance between T cell activation or tolerance.
By exhibiting functional plasticity, sDCs integrate envi-
ronmentally imprinted functional programming with the
presentation of antigens obtained from the same envi-ronment, linking environmentally responsive immunity
with antigen specificity.
Recent studies challenge this paradigm, particularly
in regard to the induction of CD8+ T cell responses es-
sential for immunity to viral infections, cancer, intracellu-
lar bacteria, and parasites. The definition of at least six
distinct DC subsets based on partially overlapping
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(A) DCs infected with vaccinia vector or lentivector were monitored for cell death by determining the number of surviving cells (left panel) or by
identification of apoptosis in DC populations by flow cytometry using Annexin-V staining (right panel) at indicated time points.
(B) OVA-lvv-transduced DCs were exposed to 1 J of UVB light to induce apoptosis. Twenty-five thousand live or irradiated lentivector-trans-
duced DCs were cocultured with OT-I cells to determine their ability to stimulate naive CD8 T cells. Mean 6 SD of triplicate wells is shown.
(C) Naive mice were immunized with 0.5 million of live or irradiated OVA-lvv-transduced DCs, and 8 days later antigen-specific in vivo killing was
determined as previously described. Mean 6 SD of two mice is shown.
(D) Naive mice were cutaneously immunized with 0.5 million live or irradiated OVA-lvv-transduced DCs, and the capacity of DCs to stimulate OT-I
cell proliferation in vivo was determined by evaluating progressive dilution of CFSE intensity. M1, nonproliferating OT-I cells. M2, proliferating
OT-I cells.phenotypic profiles, distinct patterns of expression of
TLRs, and evolving functional correlations has raised
the possibility that certain DC subsets may be special-
ized and restricted in their functional capacity (Carbone
et al., 2004; Heath et al., 2004; Serbina and Pamer, 2003).
Consistent with this, blood-derived splenic CD8a+ DCs
have been shown to play a critical role in crosspriming
CD8+ T cell immunity against cell-associated antigens
(den Haan et al., 2000). Furthermore, in direct contrast
to the current paradigm of cutaneous immunity, new
studies suggest that CD8+ T cell responses against vir-
ally encoded antigens are crossprimed by blood-
derived, LN resident CD8+ DCs, and not sDCs (Allan
et al., 2003; Belz et al., 2004; Smith et al., 2003). This
has been demonstrated for VV, HSV, and IAV. In thosestudies, following viral delivery, sDCs from skin DLNs
did not appear capable of directly presenting virally en-
coded antigens to CD8+ T cells, suggesting that sDCs
were insufficient to prime CD8+ T cell responses. Subse-
quent studies suggest that splenic CD8+ DCs also play
a dominant role in priming CD8+ T cell responses against
lymphocytic choriomeningitis virus (LCMV) and Listeria
monocytogenes (LM), although, in these systems, ani-
mals were challenged parenterally, bypassing the cuta-
neous immune system (Belz et al., 2005). Taken to-
gether, these observations have led to an alternative
model of cutaneous immune function based on the
idea that sDCs can transport antigens from the periph-
ery and transfer them to other LN resident DCs for cross-
presentation (Carbone et al., 2004; Heath et al., 2004).
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that antigen transfer between DC populations could ef-
ficiently distribute antigen to a large network of LN res-
ident DCs specialized for antigen presentation. It would,
however, require both an efficient mechanism for the
distribution of small quantities of antigen to multiple
DCs and a mechanism to translate and transfer inflam-
matory or tolerogenic signals from the periphery into
appropriate T cell responses.
Early studies demonstrating the remarkable antigen
presentation capacity of DCs suggest that CD82 DCs
could prime CD8+ T cell immunity. We and others have
demonstrated that cutaneous injection of CD82 bone
marrow-derived DCs pulsed with peptide antigens in-
duces potent antigen specific CD8+ T cell immunity (Cel-
luzzi et al., 1996; Mayordomo et al., 1995; Paglia et al.,
1996; Young and Inaba, 1996). Similarly, we have shown
that CD82 bone marrow-derived DCs can efficiently in-
ternalize and crosspresent antigens from live cells to in-
duce CD8+ T cell immunity (Celluzzi and Falo, 1998).
Studies specifically evaluating the role of sDCs in T
cell priming have shown that peptide-pulsed LCs iso-
lated from epidermis also induce potent antigen-spe-
cific CD8+ T cell responses when injected intradermally
(Celluzzi and Falo, 1997). In each of these examples, it is
formally possible that the adoptively transferred DCs
distribute antigen to collaborating resident DCs, though
no direct evidence has been reported to support this
interpretation. The relative contributions of direct prim-
ing versus crosspriming in DC adoptive transfer ap-
proaches remain controversial. Recent imaging studies
strongly suggest that injected DCs do directly prime T
cells, as evidenced by cognate interactions between la-
belled injected DCs and antigen-specific T cells, and as-
sociated T cell proliferation and activation (Bousso and
Robey, 2003; Mempel et al., 2004; Stoll et al., 2002).
Many of the models used to support the predominant
role of LN-resident CD8a+ DCs in CD8+ T cell cross prim-
ing rely on infection of skin and sDCs (Belz et al., 2004;
Smith et al., 2003). Both the cytolytic nature of these vi-
ruses and their well-described mechanisms for immune
evasion can directly or indirectly alter antigen presenta-
tion function (Bosnjak et al., 2005; Engelmayer et al.,
1999; Larsson et al., 2004; Yewdell and Haeryfar,
2005). We sought to directly address the role of sDCs
in CD8+ T cell priming by utilizing a viral vector known
to efficiently transduce DCs without inhibiting the anti-
gen processing and presentation function of infected
cells. Very recently lentivirus has been explored as a vec-
tor for genetic immunization, and preliminary studies
suggest that it is among the most potent vectors for im-
mune induction (He et al., 2005; Esslinger et al., 2003).
Importantly, we and others have shown that lentivectors
efficiently and stably transfect DCs without apparent al-
teration of DC function (He et al., 2005; Breckpot et al.,
2003). Lentivector-transfected bone marrow-derived
CD82DCs can process and present transgenic antigens
through both the class I and class II restricted process-
ing pathways and prime naive CD8+ and CD4+ T cells (He
et al., 2005). Studies we present here demonstrate the
remarkable potency of cutaneous immunization with
lentivectors. We show that a single cutaneous injection
of lentivector results in potent CD8+ T cell activation
and antigen-specific lytic activity. Lentivector immuni-zation results in potent immune responses against
model (OVA), viral (HBS), and self (TRP-2) antigens,
and a single immunization against a model tumor anti-
gen results in inhibition of tumor growth and prolonged
survival of mice bearing the highly aggressive B16 mel-
anoma. Importantly, lentivector-based immunization re-
sults in prolonged effector function that correlates with
prolonged presentation of transgenic antigens by DCs
in the DLNs. While initial immune responses induced
by lentivector are comparable in magnitude to those in-
duced by adenovector, a gold standard for genetic im-
munization, lentivectors do not appear to induce signif-
icant levels of antivector immune responses. This
obviates a major limitation of adenovirus and other viral
vectors that become ineffective for boosting or reimmu-
nization due to the presence of antivector immune re-
sponses.
In the skin DLNs, sDCs are phenotypically character-
ized as CD11c+ CD11b+CD82/loDEC205+B2202. By iso-
lating DC subsets from LNs draining the site of lentivec-
tor injection and evaluating their ability to stimulate
antigen-specific CD8+ T cells ex vivo, we demonstrate
that the CD8+ T cell-activating capacity is found pre-
dominantly in sDCs. Specifically, the ability to present
lentiviral-encoded transgenic OVA to OVA-specific
CD8+ T cells was present predominantly in DC pop-
ulations characterized in separate experiments as
CD11c+CD82/loB2202, CD11c+CD82/loCD11b+, and
CD11c+CD82/loDEC205+, all phenotypically consistent
with sDCs. Although there are at least two recognized
subsets of sDCs, LCs and dermal DCs, because they dif-
fer only by intermediate degrees of expression of these
markers, they can be difficult to distinguish using these
panels, and we did not attempt to do so (Itano et al.,
2003). This panel of phenotypic markers is sufficient to
clearly distinguish sDCs from the CD8+ DC subset
(CD11c+CD8+B2202), the plasmacytoid DC subset
(CD11c+CD82/loB220+), and the LN-resident myeloid
DC population (CD11c+CD82DEC2052) in skin DLNs.
Importantly, the methods we used were similar to
those used previously to demonstrate that sDCs do
not present cutaneously delivered viral antigens (Allan
et al., 2003; Belz et al., 2004; Smith et al., 2003). Using
the same VV construct used in those previous studies,
we verified that, after cutaneous immunization, CD8+
DCs and not sDCs presented vaccinia-encoded OVA
to OVA-specific CD8+ T cells. Thus, our experimental ap-
proach is comparable to that used previously, support-
ing the interpretation that our distinctly different results
are a consequence of the vector used for immunization
and different mechanisms of immune induction.
To further define the mechanism by which lentiviral
vectors induce immune responses, and to investigate
mechanistic differences between lentivectors and other
well-described viral vectors, we evaluated and com-
pared gene expression in vivo following lentivector
and vaccinia vector immunization. We found consider-
able differences. VV immunization resulted in rapid but
transient transgene expression in DLNs. This is consis-
tent with previous reports and a mechanism based on
expression of antigen in DCs or non-DCs, death of in-
fected cells, and crosspresentation of released antigens
by CD8+ DCs (Engelmayer et al., 1999; Humlova et al.,
2002; Larsson et al., 2001, 2004; Norbury et al., 2002).
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persistent high-level transgene expression in the DLNs
and in DLN DCs. Importantly, transgenic mRNA and pro-
tein expression was detectable exclusively in the sDC
subset, as evidenced by separate experiments demon-
strating transgenic mRNA and luciferase exclusively in
CD11c+CD82/loB2202 and CD11c+CD82/loDEC205+ DC
subsets.
Our results suggest that sDCs were primarily trans-
fected in the skin, though some transfection of sDCs
by viral particles reaching the node through the afferent
lymphatics may also occur. The time course of gene ex-
pression by sDCs is consistent with the accumulation
and persistence of transfected DCs migrating from the
skin. Furthermore, predominant presentation by a migra-
tion inhibitable, FITC+ sDC population subsequent to
FITC skin painting strongly suggests that DCs trans-
fected in the skin make important contributions to the in-
duction of the immune response we observe. The iden-
tity of DC subset(s) that have access to substances
in the afferent lymph remains controversial, with recent
reports describing uptake of soluble antigens exclu-
sively by sDCs (CD11c+CD82/loDEC205+) (Itano et al.,
2003) or LN resident blood-derived myeloid DCs
(CD11c+CD11b+DEC2052) (Sixt et al., 2005), respec-
tively. In the case of antigen uptake by sDC resident in
LNs, it is noteworthy that antigen presentation by LN res-
ident sDCs was insufficient to fully activate CD4+ T cells,
which required subsequent presentation by sDCs arriv-
ing from antigen-exposed skin (Itano et al., 2003).
Interestingly, our demonstration of sDC presentation
of antigen to CD8+ T cells is consistent with recently
published studies showing that sDCs present keratino-
cyte-derived antigens to activate naive CD8+ T cells
(Mayerova et al., 2004). Our results are also consistent
with recent studies showing that direct contact with in-
vading microbes is necessary for DCs to acquire the
ability to stimulate functional effector CD4+ T cells
(Sporri and Reis e Sousa, 2005).
These results demonstrate that sDCs can present vir-
ally encoded antigens to activate CD8+ T cells, and they
support the traditional paradigm of cutaneous immune
function in which antigen presentation and immunomo-
dulation functions are integrated into the same APC
subset, namely the sDCs. Differences in the nature of
the vectors used could explain the differences between
these results and previously published studies. Many
pathogens have evolved mechanisms for immune eva-
sion, and DCs infected by them, or exposed to signals
from infected cells, could have altered antigen presenta-
tion function (Larsson et al., 2004; Yewdell and Haeryfar,
2005). In particular, cytolytic viruses whose antigens are
presented by CD8+ DCs could drive antigen expression
in infected sDCs that die after migration to the DLNs, fa-
cilitating uptake and presentation of apoptotic debris by
LN-resident CD8+ DCs. This is supported by studies
demonstrating effective internalization and processing
of apoptotic debris by CD8+ DCs and enhanced immu-
nity generated by cytopathic self-replicating RNA-
induced apoptosis of adoptively transferred antigen ex-
pressing CD82DCs (Racanelli et al., 2004). Alternatively,
the discrepancy could be related to plasticity between
CD82 DC and CD8+ DC subsets. Some studies suggest
that CD82 DCs can subsequently become CD8+ (Moronet al., 2002), and it has been suggested that sDCs (and
LCs in particular) can upregulate CD8 expression in
the DLNs, albeit at low levels (Anjuere et al., 2000). Inter-
estingly, recent studies demonstrate expression of lan-
gerin, thought to be an LC-specific marker, in LN-resi-
dent CD8+ DCs (Bennett et al., 2005; Kissenpfennig
et al., 2005). On the other hand, a quantitative analysis
of DC subsets argues against CD82 to CD8a+ DC con-
version, and radiation chimera experiments support
the interpretation that, in some viral infections, blood-
derived CD8+ DCs rather than sDCs from skin-resident
radio-resistant sDC precursors are critical for CD8+ T
cell activation (Allan et al., 2003; Naik et al., 2003). Given
these observations, it remains possible that the collabo-
rative paradigm of cutaneous immune function can be
operable under certain specific conditions. The coexis-
tence of integrative and collaborative mechanisms of
immune induction further demonstrates the remarkable
resiliency and plasticity of DCs and the cutaneous im-
mune system.
It is tempting to speculate that the potency and dura-
bility of immune responses induced by lentivector-me-
diated genetic immunization are related to the vectors’
capacity to efficiently transfect sDCs without adversely
effecting their survival, plasticity, or antigen processing
and presentation function. Further studies elucidating
the role of DC subsets in the generation and control of
immunity against cutaneously delivered antigens will
be necessary to develop effective strategies to target
and engineer the function of DC subsets in vivo.
Experimental Procedures
Mice
C57BL/6 and OVA TCR transgenic mice OT-I were purchased from
Jackson Laboratory (Bar Harbor, Maine). The mice were housed un-
der SPF conditions in the central animal facility of the University of
Pittsburgh. Handling of the mice was according to institutional
guidelines of the University of Pittsburgh.
Viral Vectors
The third-generation lentivectors OVA-lvv and EGFP-lvv expressing
OVA and EGFP were described as before (He et al., 2005). HBV S
antigen was amplified by PCR from template plasmid pRc/CMV-
HBs(S) (Aldevron, Fargo, North Dakota). EGFP-TRP2181–188 fusion
gene was constructed as previously described (Zhang et al.,
2004). Briefly, the TRP2 epitope of aa 181–188 was fused next to
the EGFP protein gene to form the EGFP-TRP2 fusion gene and
then cloned into lentivector. Lentivector expressing the luciferase
gene was also constructed. The resulting lentivectors were desig-
nated as HBS-lvv, TRP2-lvv, Luc-lvv, or EGFP-TRP2-lvv and shown
in Figure S1. Lentivectors were prepared and concentrated as de-
scribed (He et al., 2005). Adenoviral vectors were kindly provided
by Dr. Robbins of the University of Pittsburgh. The vaccinia vector
expressing OVA was kindly provided by Dr. Yewdell, National Insti-
tutes of Health. Handling of viral vectors was according to the guide-
lines of BSL-2+ laboratories established by the Recombinant DNA
Committee of the University of Pittsburgh.
Genetic Immunization
For gene gun bombardment, plasmid DNA coated bullets were ad-
ministered onto the abdomen of mice after the hair was shaved.
Four shots with approximately 20 mg of DNA were administered.
For intramuscular injection, mice were anesthetized with isoflurane,
and then 100 mg of plasmid DNA in 100 ml of saline was injected into
gluteal muscles after incision of the skin. Immunizations with re-
combinant viral vectors were conducted by footpad injection in
50 ml containing the indicated doses.
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This assay was performed as described previously (He et al., 2005).
Briefly, OT-I T cells were isolated from the spleen and LN of OVA TCR
transgenic mice, and the purity of OT-I T cells was determined to be
above 95%. OT-I cells or CFSE labelled OT-I cells (150,000) were co-
cultured with indicated number of DC subsets for 2–3 days. In exper-
iments shown in Figure 7, bone marrow-derived DCs were gener-
ated and transduced with lentivector as described previously (He
et al., 2005). Where indicated, DCs were exposed to 1J of UVB to in-
duce apoptosis as described (Nicolo et al., 2001). Proliferation of
OT-I cells was measured by reduction of CFSE intensity or by 3H-
thymidine incorporation. In some experiments, supernatant was
saved to determine IFN-g cytokine production. In vivo antigen-spe-
cific lytic activity was measured by in vivo killing assay as described
previously (Barchet et al., 2000; He et al., 2005).
In Vivo Antigen Presentation Assay
In vivo antigen presentation assay was performed as described
(Stock et al., 2004). Briefly, mice were injected in the footpad with
1 million TU of lentivector (OVA-lvv) or 1 million pfu of vaccinia vector
(OVA-VV). At the indicated time points, 10 million OT-I cells labelled
with CFSE were administered through tail vein. Forty-eight hours af-
ter injection, draining popliteal LN and contralateral LN cells were
collected and stained with anti-Va2-PE and anti-Vb5.1-5.2-biotin+
APC-labelled Streptavidin to identify OT-I cells, and proliferation of
OT-I cells was measured by reduction of CFSE intensity.
Flow Cytometry Analysis
Cells were collected and washed with PBS. One half million cells
were added to each staining tube. Anti-CD11c-FITC, anti-CD8-
APC, anti-B220-PE, anti-CD11b-PE, anti-IFN-g-APC, anti-Va2-PE,
and anti-Vb5.1-5.2-biotin antibodies were purchased from BD Phar-
mingen. APC-labelled Streptoavidin was used as secondary reagent
at 1:1000 dilution. Anti-DEC205-PE was from Cedarlane (Hornby,
Ontario, Canada). Cells were fixed, and 30,000 events were collected
and analyzed. For DC subset isolation, CD11c+ DCs were enriched
from draining LN cells by depleting B and T cells using magnetic
beads. Enriched DCs were stained for CD11c, CD8, and either
B220, CD11b, or DEC205, and subsets were gated and sorted as de-
scribed. To evaluate intracellular expression of IFN-g, splenocytes
were collected and stimulated in vitro for 4 hr by adding OVA class
I peptide SIINFEKL in the presence of Golgistop to block the secre-
tion of IFN-g. Cells were then collected and stained for CD8 and in-
tracellular IFN-g using an intracellular staining kit according to the
manufacturer (BD Pharmingen, San Diego, California).
Tumor Growth and Immunization
Mice were inoculated with 0.1 million B16-OVA cells in 50 ml of PBS
s.c. Three days later, 1 million TU of lentivector OVA-lvv or EGFP-lvv
was injected into the footpads of the mice. Tumor growth was mon-
itored by measuring the perpendicular diameter of the tumor, and
survival was recorded daily.
RT-PCR
Total RNA was isolated from total LN cells or sorted DC subsets us-
ing RNA isolation kit RNAqueous-4PCR or RNAqueous-Micro
(Ambion, Austin, Texas). The indicated amount of RNA was utilized
for each RT-PCR using Access RT-PCR system (Promega, Madison,
Wisconsin) with OVA-specific primers (OVA-Forward, 50-TAAGGG
GAAACACAT-CTGCC-30; OVA-Reverse, 50-CAGATCAAGCCAGAG
AGCTCATC-30). Amplification of ribosomal S15 mRNA was con-
ducted as internal control using specific primers (S15-Forward, 50-
TTCCGCAAGTTCACCTACC-30; S15-Reverse, 50-CGGGCCGGCCA
TG-CTTTACG-30).
DC Migration
The hind legs of mice were shaved and injected intradermally with
lentivector OVA-lvv with or without the DC migration inhibitor pertu-
sis toxin (0.5 mg). The injected area was then painted with 0.5 mg/ml
of FITC in acetone/dibutylphthalate solution. Two days later, drain-
ing LNs were harvested, and DCs were analyzed and purified by flow
cytometery for functional analysis.Statistic Analysis
Unpaired t test analysis (two-tailed) was used to determine whether
the differences among the tumor size in OVA-lvv, EGFP-lvv, and
control groups were significant.
Supplemental Data
Supplemental Data include seven figures and can be found with this
article online at http://www.immunity.com/cgi/content/full/24/5/
643/DC1/.
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